Ophthalmic Microemulsion Formulation for Dry Eye Lubrication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease (DED) are often costly, have mixed efficacy, and can cause ocular burning, leading to patient discomfort and inadequate relief from chronic symptoms.
Innovation Solution
The development of ophthalmic pharmaceutical formulations that include lubricity-promoting ingredients, surfactants, mucoadhesive polymers, osmoprotectants, and nutritional components such as amino acids and vitamins, formulated as microemulsions or nanoemulsions to enhance ocular health, improve eye comfort, and facilitate the delivery of pharmacological agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prescription products are used to treat dry eye disease, then some therapeutic effect may be achieved, but patient discomfort increases due to ocular burning and high cost
Solution Approach 1:
The invention uses composite lipid materials combining multiple lipid types (cholesterol, phospholipids, free fatty acids, triglycerides) with specific ratios to create a tear film substitute that mimics natural tears more closely, reducing ocular burning while maintaining therapeutic effectiveness
Solution Approach 2:
The invention optimizes specific parameters including lipid composition ratios, osmolarity (280-320 mOsm/L), pH (6.5-7.5), and viscosity to match physiological conditions, thereby reducing ocular burning sensation while preserving therapeutic action
2Object-affected harmful factors
If conventional tear substitutes are used, then some relief from dryness is provided, but visual blurring occurs reducing patient comfort
Solution Approach 1:
The invention carefully controls viscosity parameters and lipid particle size distribution to ensure the formulation remains optically clear while providing adequate lubrication, eliminating visual blurring while maintaining dryness relief
Solution Approach 2:
The formulation provides different functional properties in different phases: the aqueous phase maintains optical clarity for vision, while the lipid microemulsion droplets provide lubrication and dryness relief, achieving local quality differentiation
3Object-affected harmful factors
If lubricating agents are applied to relieve dry eye symptoms, then comfort is improved, but the complexity of the formulation increases
Solution Approach 1:
The lipid microemulsion system performs multiple functions simultaneously: lubrication, tear film stabilization, drug delivery vehicle, and osmotic balance, reducing the need for separate formulation components and simplifying the overall formulation complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These formulations provide effective relief from dry eye symptoms by improving lubrication, reducing discomfort, and promoting corneal health, while also serving as a platform for delivering active agents to treat ocular conditions with enhanced patient comfort and reduced visual blurring.
Implementation Method 1
the ophthalmic pharmaceutical formulations are in the form of a microemulsion or nanoemulsion formed from lipids and/or natural plant oils and surfactants
Implementation Method 2
surfactant(s) that solubilize lipid and/or plant oil ingredient(s) and assist in lubrication, and assist in easily spreading over hydrophobic surfaces
Implementation Method 3
mucoadhesive polymer(s) that demonstrate shear thinning flow behavior
Implementation Method 4
osmoprotectants. In some embodiments, the same ingredient can provide the effects of one or more of the lubricity-promoting ingredient(s), surfactant(s), lipid and/or plant oil ingredient(s), and/or mucoadhesive polymer(s)
Data Source
AI summary
The invention describes ophthalmic pharmaceutical formulations comprising pharmaceutical ingredients to address DED symptoms. In one aspect of the invention, an ophthalmic pharmaceutical formulation comprises: 1) lubricity-promoting ingredient(s) such as those listed in the FDA over the counter (OTC) monograph for ophthalmics as demulcents and 2) surfactant(s) that solubilize lipids, assist in lubrication, and assist in easily spreading over hydrophobic surfaces; and/or 3) lipid and/or plant oil ingredient(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication; and/or 4) mucoadhesive and viscosity promoting polymer(s) that demonstrate shear thinning flow behavior. The pharmaceutical ingredients and osmoprotectant/tonicity ingredients are combined with ingredients that provide direct to the eye nutritional support that is comprehensive in nature. The total nutritional approach uses metabolically important tear fluid amino acids, vitamins, and both fatty acids/triglycerides and sugar molecules as energy sources. The invention results in both improved eye health and improved dry eye patient comfort.